SCHEMBL119377

SCHEMBL119377

CO[PH](=O)Oc1c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c2c1=O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLH Q9Y253 8/20 0.75
KDM4E B2RXH2 5/20 0.75
POLB P06746 4/20 0.75
RECQL P46063 4/20 0.75
MEN1 O00255 4/20 0.75
KMT2A Q03164 4/20 0.75
APEX1 P27695 3/20 0.75
GAA P10253 3/20 0.75
HSD17B10 Q99714 3/20 0.75
MMP1 P03956 2/20 0.75
MAPT P10636 2/20 0.75
BLM P54132 2/20 0.75
HTT P42858 1/20 0.75
NOX4 Q9NPH5 2/20 0.64
PLG P00747 1/20 0.64
TUBB4A P04350 1/20 0.62
TUBB P07437 1/20 0.62
TUBA3C P0DPH7 1/20 0.62
TUBA1B P68363 1/20 0.62
TUBA4A P68366 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL120009 0.87 POLH (0.72) POLHKDM4EPOLBRECQLMEN1
3-O-Methylquercetin SCHEMBL380558 0.86 POLH (1.00) POLHKDM4EPOLBRECQLMEN1
3-O-Methylquercetin SCHEMBL29897544 0.86 POLH (1.00) POLHKDM4EPOLBRECQLMEN1
SCHEMBL17102291 0.84 POLH (0.82) POLHKDM4EPOLBRECQLMEN1
SCHEMBL14786208 0.83 POLH (0.81) POLHKDM4EPOLBRECQLMEN1
SCHEMBL28297226 0.82 POLH (0.79) POLHKDM4EPOLBRECQLMEN1
SCHEMBL10861623 0.81 POLH (0.78) POLHKDM4EPOLBRECQLMEN1
SCHEMBL3757879 0.81 CYP1A2 (0.76) POLHKDM4EPOLBRECQLMEN1
SCHEMBL9512509 0.81 POLH (0.77) POLHKDM4EPOLBRECQLMEN1
SCHEMBL31236662 0.81 POLH (0.76) POLHKDM4EPOLBRECQLMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424541-A2 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT Limerick BioPharma, Inc. (US) 2012-03-07 EP disclosed
US-20100297020-A1 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA, INC. (US) 2010-11-25 US disclosed
WO-2010129138-A2 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297020-A1 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT PC, PCK1, PYGL POLH 2494/4885KDM4E 3745/4885POLB 2003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.